ArticleEXCLI journal2012
Prevalence of extended spectrum beta-lactamase production among uropathogens in south Mumbai and its antibiogram pattern.
Article in EXCLI journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 34 citations in OpenAlex.
- CkP1 bacteriophage, a S16-like myovirus that recognizes Citrobacter koseri lipopolysaccharide through its long tail fibers.Applied microbiology and biotechnology · 2023Article
- Extended-Spectrum Beta-Lactamase-ProducingFrontiers in public health · 2020Article
- Nanoemulsions of Green Tea Catechins and Other Natural Compounds for the Treatment of Urinary Tract Infection: Antibacterial Analysis.Advanced pharmaceutical bulletin · 2019Article
- Molecular characterization of extended-spectrum β-lactamases among clinical isolates ofThe Indian journal of medical research · 2019Article
- Article
- Antimicrobial Susceptibility Profile of Extended Spectrum β-Lactamase (ESBL) Producing Escherichia coli from Various Clinical Samples.Infectious diseases · 2014Article
- Antimicrobial susceptibility pattern of extended-spectrum beta- lactamase producing Klebsiella pneumoniae clinical isolates in an Indian tertiary hospital.Journal of research in pharmacy practiceArticle
- Study of inhibitory potential and percent inhibition of oil ofIndian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-lactams are the most widely used group of antimicrobials. However, increasing resistance to these valuable drugs in uropathogens, mediated principally by β-lactamases, has become a major concern. The present study was undertaken to determine the prevalence of Extended Spectrum β-Lactamase (ESBL) producers in clinical isolates of urine specimens, collected from various healthcare centres across south Mumbai. A total of 195 gram negative urine isolates were identified as Pseudomonas aeruginosa (13), Proteus mirabilis (21), Klebsiella pneumoniae (29), Escherichia coli (96), Enterobacter aerogenes (1), Enterobacter cloacae (1), Enterococcus fecalis (1), Morganella morganii (1), Citrobacter diversus (16), Citrobacter amalonaticus (5) and Proteus vulgaris (11). Antimicrobial Susceptibility Testing (AST) by Kirby-Bauer method showed 43.07 % (84/195) of the isolates were resistant to more than 70 % of the antibiotics used. Confirmatory screening using a combination of Double Disk Synergy Test (DDST), Phenotypic Confirmatory Disc Diffusion Test (PCDDT) and E-test revealed the overall prevalence of ESBL producers to be 34.71 % (68/195). The study showed 72.05 % of the ESBL producers to be resistant to fluoroquinolones, highlighting its extensive use in the region of south Mumbai. All ESBL producers were found to be sensitive to Imipenem whereas 82.36 % showed susceptibility to Amikacin making these 2 antibiotics the most effective choice of drug against ESBLs. In order to ensure rational treatment of highly resistant pathogens, the occurrence of ESBL and its primary studies may serve as a base for further research and findings.
Indexed as
Identifiers
27418912PMC4942789W2259217296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.